Asset-light pharma services are entering a new era as pharmaceutical companies grapple with increasingly complex regulatory, commercial and technological challenges. Although growth in pharma commercialisation has slowed sharply from pre-pandemic…
Asset-light pharma services enter new era: insight from the IIH Private Capital Conference
…
…






